ClinicalTrials.gg
CompletedNCT04024462Updated Feb 20, 2026Results posted

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

A Phase 3 interventional study of Pertuzumab IV and Trastuzumab IV in HER2-positive Early Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
36th of 104
200 · median 100
Started
2020
with 4 others
Phase 3
23 of 104
2 open now
Registered
54th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 5 that started in 2020, is one of 23 in phase 3, and was the 54th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics, efficacy, and safety of the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) as compared with those of the pertuzumab intravenous (IV) and trastuzumab IV formulations in Chinese participants with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

03

Conditions studied

  • HER2-positive Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comply with the study protocol, in the investigator's judgment
  • (ECOG) Performance Status greater or equal to (≤)1
  • Stage II-IIIC (T2-T4 plus any N, or any T plus N1-3, M0), locally advanced, inflammatory, or early-stage, unilateral, and confirmed invasive breast cancer
  • Primary tumor greater than (>)2 centimeters (cm) in diameter, or node-positive disease (clinically or on imaging, and node positivity confirmed with cytology and/or histopathology)
  • Human Epidermal Growth Factor Receptor 2 ()-positive breast cancer confirmed by a central laboratory prior to study enrollment. HER2-positive status will be determined based on pretreatment breast material and defined as 3+ by immunohistochemistry (IHC) and/or positive by HER2 amplification by in situ hybridization (ISH) with a ratio of ≥2 for the number of HER2 gene copies to the number of signals for chromosome 17 copies
  • Hormone receptor status of the primary tumor, centrally confirmed
  • Patient agreement to undergo mastectomy or breast conserving surgery after therapy
  • Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue for central confirmation of HER2, hormone receptor status, and PIK3CA mutational analyses
  • Baseline (LVEF) ≥55% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
  • For women of (WOCBP) who are sexually active: agreement to remain abstinent (refrain from heterosexual intercourse) or use one highly effective non-hormonal method with a failure rate of less than (\<)1% per year, or two effective non-hormonal contraceptive methods during the treatment period and for 7 months after the last dose of HER2-targeted therapy, and agreement to refrain from donating eggs during this same period
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom in combination with a spermicidal foam, gel, film, cream, or suppository, and agreement to refrain from donating sperm, as specified in the protocol
  • A negative serum pregnancy test must be available prior to randomization for WOCBP (premenopausal women and women \<12 months after the onset of menopause), unless they have undergone surgical sterilization (removal of ovaries and/or uterus)
  • No major surgical procedure unrelated to breast cancer within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment

Exclusion criteria

Exclusion Criteria:

  • Stage IV () breast cancer
  • History of invasive breast cancer
  • History of concurrent or previously treated non-breast except for appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas, including cervix, colon, and skin
  • Have received any previous systemic therapy (including chemotherapy, immunotherapy, -targeted agents, endocrine therapy [selective estrogen receptor modulators, aromatase inhibitors], and antitumor vaccines) for treatment or prevention of breast cancer, or radiation therapy for treatment of cancer
  • Have a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) if they have received any systemic therapy for its treatment or radiation therapy to the ipsilateral breast
  • High-risk for breast cancer and have received chemopreventative drugs in the past
  • Multicentric (multiple tumors involving more than one quadrant) breast cancer, unless all tumors are HER2-positive
  • Bilateral breast cancer
  • Have undergone an excisional of primary tumor and/or axillary lymph nodes
  • Axillary lymph node dissection (ALND) prior to initiation of therapy
  • Sentinel lymph node biopsy (SLNB) prior to neoadjuvant therapy
  • Treatment with any drug within 28 days prior to randomization
  • Serious cardiac illness or medical conditions
  • Inadequate bone marrow function
  • Impaired liver function
  • Inadequate renal function with serum creatinine >1.5X (ULN)
  • Current severe, uncontrolled systemic disease that may interfere with planned treatment (e.g., cardiovascular, pulmonary, or metabolic disease; wound-healing disorders)
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the last dose of HER2-targeted therapy
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • Known active liver disease, for example, active viral hepatitis infection (i.e., or ), hepatic disorders, or sclerosing cholangitis
  • Concurrent, serious, uncontrolled infections, or known infection with
  • Known to study drugs, , and/or murine proteins
  • Current chronic daily treatment with (dose >10 milligrams [mg] methylprednisolone or equivalent excluding inhaled steroids)
  • History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, colon, skin, and/or non-melanoma skin carcinoma
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural heart disease (e.g., severe LVSD, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long syndrome
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy

    Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.

    Drug: Pertuzumab IV · Drug: Trastuzumab IV · Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel · Procedure: Surgery · Radiation: Post-Operative Radiotherapy · Drug: Hormone Therapy

  • Experimental
    Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy

    Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.

    Drug: Pertuzumab and Trastuzumab FDC SC · Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel · Procedure: Surgery · Radiation: Post-Operative Radiotherapy · Drug: Hormone Therapy

Interventions

  • Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.

    Also known as: Perjeta, RO4368451

  • Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.

    Also known as: Herceptin, RO0452317

  • DrugPertuzumab and Trastuzumab FDC SC

    Drug page: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

    The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.

    Also known as: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, RG6264, RO7198574

  • Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.

  • Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.

  • Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.

  • ProcedureSurgery

    Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.

  • RadiationPost-Operative Radiotherapy

    If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).

  • DrugHormone Therapy

    For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.

06

What researchers measure

Primary outcomes

  1. Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)

    The observed pertuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a Cycle 7 subcutaneous injection site other than thigh was used, if the Cycle 8 IV pre-dose and post-dose PK samples were switched, and an assay error impacting Ctrough measurement.

    Time frame: Pre-dose at Cycle 8 (one cycle is 21 days)

  2. Serum Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)

    The observed trastuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a Cycle 7 subcutaneous injection site other than thigh was used, if the Cycle 8 IV pre-dose and post-dose PK samples were switched, and an assay error impacting Ctrough measurement.

    Time frame: Pre-dose at Cycle 8 (one cycle is 21 days)

Secondary outcomes

  1. Percentage of Participants With Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment

    Total pathological complete response (tpCR) was defined as eradication of invasive disease in the breast and axilla; that is, ypT0/is ypN0, according to the local pathologists' assessment. Pathologic response to therapy was determined at the time of surgery. The tpCR rate is the percentage of participants in the ITT population who achieved a tpCR. Participants with missing data for tpCR (i.e., do not undergo surgery or have an invalid pCR assessment) were included in the analysis and classified as non-responders. Rates of tpCR were calculated in each treatment arm and were assessed using the difference between the Arm B: Pertuzumab and Trastuzumab FDC SC and the Arm A: Pertuzumab IV and Trastuzumab IV tpCR rates and corresponding 95% Clopper-Pearson confidence intervals (CIs). The difference between the tpCR rates along with corresponding 95% Hauck-Anderson CIs were calculated.

    Time frame: Following completion of surgery (up to 33 weeks)

  2. Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Invasive Disease-Free Survival (iDFS; Excluding Second Primary Non-Breast Cancer [SPNBC]) Criteria

    iDFS (excluding SPNBC) is defined as the time from the first date of no disease (i.e., the date of primary surgery) to the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer reccurrence; distant recurrence; contralateral invasive breast cancer; or death attributable to any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.

    Time frame: From date of surgery to iDFS (excluding SPNBC) event (up to 5 years)

  3. Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to iDFS (Including SPNBC) Criteria

    iDFS including SPNBC is defined in the same way as iDFS but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

    Time frame: From date of surgery to iDFS (including SPNBC) event (up to 5 years)

  4. Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Event-Free Survival (EFS; Excluding SPNBC) Criteria

    EFS (excluding SPNBC) is defined as the time from enrollment to the first occurrence of one of the following events: breast cancer progression; breast cancer recurrence; or death from any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.

    Time frame: From baseline to EFS (excluding SPNBC) event (up to 5.5 years)

  5. Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to EFS (Including SPNBC) Criteria

    EFS including SPNBC is defined in the same way as EFS, but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

    Time frame: From baseline to EFS (including SPNBC) event (up to 5.5 years)

  6. Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Distant Recurrence-Free Interval (DRFI) Criteria

    DRFI is defined as the time between randomization and the date of distant breast cancer recurrence.

    Time frame: From baseline to DFRI event (up to 5.5 years)

  7. Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival

    Time frame: From baseline to death from any cause (up to 5.5 years)

  8. Number of Participants With at Least One Adverse Event by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 (NCI CTCAE v4)

    Time frame: From baseline until study completion (up to 5.5 years)

  9. Number of Participants With a Primary Cardiac Event

    A primary cardiac event is defined as either a symptomatic ejection fraction decrease (heart failure) of New York Heart Association (NYHA) Class III/IV and a drop in left ventricular ejection fraction (LVEF) of at least 10-percentage points from baseline and to below 50%, or a definite or probable cardiac death. NYHA Class III is defined as: marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. NYHA Class IV is defined as: Inability to carry on any physical activity without discomfort; symptoms of cardiac insufficiency at rest; if any physical activity is undertaken, discomfort is increased. Definite cardiac death is defined as death due to heart failure, myocardial infarction, or documented primary arrhythmia. Probable cardiac death is defined as sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, etc.) without documented etiology.

    Time frame: From baseline until study completion (up to 5.5 years)

  10. Number of Participants With a Secondary Cardiac Event, Defined as an Asymptomatic or Mildly Symptomatic Left Ventricular Systolic Dysfunction (LVSD) of NYHA Class II

    An LVSD ("Ejection fraction decreased") of NYHA Class II is defined as a left ventricular ejection fraction (LVEF) decrease of ≥10-percentage points below the baseline measurement to an absolute LVEF value of \<50%, confirmed by a second LVEF assessment within approximately 3 weeks also showing a documented drop.

    Time frame: From baseline until study completion (up to 5.5 years)

07

Results

Posted Feb 16, 2023

Participant flow

Participants were enrolled at 18 investigational sites in China.

Participant flow — Overall Study
MilestoneArm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
Started10199
Completed neoadjuvant treatment (24 weeks)9695
Completed surgery (<9 weeks)9493
Started adjuvant treatment8989
Completed adjuvant treatment (42 weeks)1214
Started follow-up (≥3 years)2320
Completed00
Not completed10199
Withdrew: Withdrawal by subject67
Withdrew: Progressive disease01
Withdrew: Adverse event01
Withdrew: Death01
Withdrew: Lost to follow-up10
Withdrew: Ongoing in the study9489

Outcome measures

PrimarySerum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)

The observed pertuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a Cycle 7 subcutaneous injection site other than thigh was used, if the Cycle 8 IV pre-dose and post-dose PK samples were switched, and an assay error impacting Ctrough measurement.

Time frame:
Pre-dose at Cycle 8 (one cycle is 21 days)
Reported as:
Geometric mean · micrograms per millilitre (μg/mL)
Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)
micrograms per millilitre (μg/mL)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)69.9 ± 30.874.6 ± 30.5
Statistical analysis
  • Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy vs Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy · Geometric mean ratio: 1.07 · 90% CI 0.99 to 1.15The CtroughSC/CtroughIV geometric mean ratio was calculated as the SC dose of pertuzumab (Arm B) relative to the pertuzumab IV dose (Arm A).
PrimarySerum Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)

The observed trastuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a Cycle 7 subcutaneous injection site other than thigh was used, if the Cycle 8 IV pre-dose and post-dose PK samples were switched, and an assay error impacting Ctrough measurement.

Time frame:
Pre-dose at Cycle 8 (one cycle is 21 days)
Reported as:
Geometric mean · micrograms per milllilitre (μg/mL)
Serum Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)
micrograms per milllilitre (μg/mL)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
Serum Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)33.6 ± 28.852.1 ± 32.5
Statistical analysis
  • Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy vs Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy · Geometric mean ratio: 1.55 · 90% CI 1.44 to 1.67The CtroughSC/CtroughIV geometric mean ratio was calculated as the SC dose of trastuzumab (Arm B) relative to the trastuzumab IV dose (Arm A).
SecondaryPercentage of Participants With Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment

Total pathological complete response (tpCR) was defined as eradication of invasive disease in the breast and axilla; that is, ypT0/is ypN0, according to the local pathologists' assessment. Pathologic response to therapy was determined at the time of surgery. The tpCR rate is the percentage of participants in the ITT population who achieved a tpCR. Participants with missing data for tpCR (i.e., do not undergo surgery or have an invalid pCR assessment) were included in the analysis and classified as non-responders. Rates of tpCR were calculated in each treatment arm and were assessed using the difference between the Arm B: Pertuzumab and Trastuzumab FDC SC and the Arm A: Pertuzumab IV and Trastuzumab IV tpCR rates and corresponding 95% Clopper-Pearson confidence intervals (CIs). The difference between the tpCR rates along with corresponding 95% Hauck-Anderson CIs were calculated.

Time frame:
Following completion of surgery (up to 33 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment
percentage of participantsArm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
Percentage of Participants With Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment56.4 (46.20 to 66.28)55.6 (45.22 to 65.55)
Statistical analysis
  • Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy vs Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy · Difference in tpcr rate: -0.88 · 95% CI -15.21 to 13.45Difference in tpCR rate was calculated as Arm B: PH FDC SC minus Arm A: P+H IV.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Invasive Disease-Free Survival (iDFS; Excluding Second Primary Non-Breast Cancer [SPNBC]) Criteria

iDFS (excluding SPNBC) is defined as the time from the first date of no disease (i.e., the date of primary surgery) to the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer reccurrence; distant recurrence; contralateral invasive breast cancer; or death attributable to any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.

Time frame:
From date of surgery to iDFS (excluding SPNBC) event (up to 5 years)

Results for this outcome have not been posted.

SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to iDFS (Including SPNBC) Criteria

iDFS including SPNBC is defined in the same way as iDFS but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

Time frame:
From date of surgery to iDFS (including SPNBC) event (up to 5 years)

Results for this outcome have not been posted.

SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Event-Free Survival (EFS; Excluding SPNBC) Criteria

EFS (excluding SPNBC) is defined as the time from enrollment to the first occurrence of one of the following events: breast cancer progression; breast cancer recurrence; or death from any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.

Time frame:
From baseline to EFS (excluding SPNBC) event (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to EFS (Including SPNBC) Criteria

EFS including SPNBC is defined in the same way as EFS, but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

Time frame:
From baseline to EFS (including SPNBC) event (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Distant Recurrence-Free Interval (DRFI) Criteria

DRFI is defined as the time between randomization and the date of distant breast cancer recurrence.

Time frame:
From baseline to DFRI event (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryKaplan-Meier Estimate of the Percentage of Participants in Overall Survival
Time frame:
From baseline to death from any cause (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With at Least One Adverse Event by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 (NCI CTCAE v4)
Time frame:
From baseline until study completion (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With a Primary Cardiac Event

A primary cardiac event is defined as either a symptomatic ejection fraction decrease (heart failure) of New York Heart Association (NYHA) Class III/IV and a drop in left ventricular ejection fraction (LVEF) of at least 10-percentage points from baseline and to below 50%, or a definite or probable cardiac death. NYHA Class III is defined as: marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. NYHA Class IV is defined as: Inability to carry on any physical activity without discomfort; symptoms of cardiac insufficiency at rest; if any physical activity is undertaken, discomfort is increased. Definite cardiac death is defined as death due to heart failure, myocardial infarction, or documented primary arrhythmia. Probable cardiac death is defined as sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, etc.) without documented etiology.

Time frame:
From baseline until study completion (up to 5.5 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With a Secondary Cardiac Event, Defined as an Asymptomatic or Mildly Symptomatic Left Ventricular Systolic Dysfunction (LVSD) of NYHA Class II

An LVSD ("Ejection fraction decreased") of NYHA Class II is defined as a left ventricular ejection fraction (LVEF) decrease of ≥10-percentage points below the baseline measurement to an absolute LVEF value of \<50%, confirmed by a second LVEF assessment within approximately 3 weeks also showing a documented drop.

Time frame:
From baseline until study completion (up to 5.5 years)

Results for this outcome have not been posted.

Adverse events

Collected over From baseline until the primary completion date (up to approximately 1 year, 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy0/100 (0%)19/100 (19%)96/100 (96%)
Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy1/100 (1%)18/100 (18%)98/100 (98%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventArm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
ALANINE AMINOTRANSFERASE INCREASEDInvestigations4/1001/100
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/1003/100
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations3/1001/100
NEUTROPHIL COUNT DECREASEDInvestigations3/1001/100
WHITE BLOOD CELL COUNT DECREASEDInvestigations3/1002/100
POSTOPERATIVE WOUND INFECTIONInfections and infestations0/1002/100
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/1001/100
ANAEMIABlood and lymphatic system disorders0/1001/100
MYELOSUPPRESSIONBlood and lymphatic system disorders1/1001/100
CARDIAC FAILURECardiac disorders0/1001/100
Most frequent other events
Showing 10 of 49
Most frequent other events
EventArm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
ALOPECIASkin and subcutaneous tissue disorders58/10066/100
ANAEMIABlood and lymphatic system disorders63/10065/100
NEUTROPHIL COUNT DECREASEDInvestigations59/10060/100
WHITE BLOOD CELL COUNT DECREASEDInvestigations46/10056/100
NAUSEAGastrointestinal disorders48/10045/100
VOMITINGGastrointestinal disorders42/10046/100
ALANINE AMINOTRANSFERASE INCREASEDInvestigations39/10046/100
DIARRHOEAGastrointestinal disorders39/10027/100
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations39/10038/100
LEUKOPENIABlood and lymphatic system disorders25/10017/100

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
Mean51.17 ± 10.5550.42 ± 10.0150.80 ± 10.27
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
Female10199200
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino10199200
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
Asian10199200
Randomization Stratification Factors: Hormone Receptor Status
Randomization Stratification Factors: Hormone Receptor Status(Participants)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
ER Negative and PgR Negative5151102
ER Positive and PgR Positive504898
Randomization Stratification Factors: Clinical Stage at Presentation
Randomization Stratification Factors: Clinical Stage at Presentation(Participants)Arm A: Pertuzumab IV + Trastuzumab IV + ChemotherapyArm B: Pertuzumab and Trastuzumab FDC SC + ChemotherapyTotal
Stage II-IIIA7070140
Stage IIIB-IIIC312960
08

Study locations

18 sites
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Jilin Cancer Hospital
    Changchun, 130012, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • The 900th Hospital of PLA joint service support force
    Fuzhou, 110016, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Shandong Cancer Hospital
    Jinan, 250117, China
  • Jiangsu Province Hospital
    Nanjing, 210036, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, 266003, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Hebei Medical University Fourth Hospital
    Shijiazhuang, 050035, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430023, China
  • Hubei Cancer Hospital
    Wuhan, 430079, China
  • The First Affiliated Hospital of Xian Jiao Tong University
    Xi'an, 710061, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Dec 2021, 22 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 22 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 18, 2019
StartActual
Feb 5, 2020
Primary completionActual
Dec 13, 2021
CompletionActual
Jan 19, 2026
Results first posted
Feb 16, 2023
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04024462
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Feb 5, 2020
Primary completion
Dec 13, 2021
Completion
Jan 19, 2026
Results posted
Feb 16, 2023
Last update
Feb 20, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pertuzumab · Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

Start the discussion